Reports
Sale
Global Autogenous Vaccines Market Size, Trends, Research, Report: By Strain Type: Bacterial Strain, Virus Strain; By End User: Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, Others; Regional Analysis; Patent Analysis; Grants Analysis; Funding Analysis; Partnership and Collaborations Analysis; Supplier Landscape; 2024-2032
Global Autogenous Vaccines Market Outlook
The global autogenous vaccines market size was valued at USD 129.4 million in 2023, driven by the rising prevalence of contagious diseases across the globe as it is generating demand for customised autogenous vaccines. The market is anticipated to grow at a CAGR of 5.6% during the forecast period 2024-2032 to reach a value of USD 212 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Provision of Funds by Several Governments is Aiding the Growth of Autogenous Vaccines Industry
The market for autogenous vaccines is driven by the rising provision of funds by several governments and international communities of public and private benefactors for the control and eradication programmes. For example, European Animal Health Strategy Programs have contributed significantly to the industry. The rising focus of government organisations towards the immunisation of animals is expected to propel the market growth over the forecast period. Further, the international agencies and organisations like Center for Disease Prevention and Control, Food and Agriculture Organization, and World Organization for Animal Health (OIE) have significantly contributed to the reduction of animal diseases and regulating and controlling programmes for animal diseases. Besides, the market is influenced by the growing focus on innovations for the prevention and treatment of zoonotic diseases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autogenous Vaccines: Market Segmentation
An autogenous vaccine is refers to a vaccine that is developed from cultures of microorganisms accumulated from individuals and then used to immunise the same individual against further propagation and development of the same microorganisms.
On the basis of strain type, the market is divided into:
- Bacterial Strain
- Virus Strain
Based on end use, the industry can be segmented into:
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institutes
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Prevalence of Contagious Diseases to Aid the Market Growth of Autogenous Vaccines Industry
The market for autogenous vaccines is driven by the rising prevalence of contagious diseases across the globe as it is generating demand for customised autogenous vaccines. Animals are susceptible to a wide range of contagious diseases like pink eyes and peste des petits ruminants (PPR) / goat plague, a highly contagious disease that generally affects ruminants. As reported by the Food and Agricultural Organization, peste des petits ruminants (PPR) virus or goat plague can contaminate approximately 90% of small ruminant inhabitants. The outbreak of contagious diseases severely interrupts livestock production, leading to direct and indirect financial losses. The government organisations as well as public organisations contribute the economic resources for the prevention and control of contagious infection in livestock, which is expected to facilitate the market growth of autogenous vaccines during the forecast period.
Key Industry Players in the Global Autogenous Vaccines Market
The report gives a detailed analysis of the following key players in the global autogenous vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Newport Laboratories, Inc.
- Elanco Animal Health Inc.
- Cambridge Technologies
- Hygieia Biological Laboratories
- AniCon Labor GmbH
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Strain Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Autogenous Vaccine Market Overview
3.1 Global Autogenous Vaccine Market Historical Value (2017-2023)
3.2 Global Autogenous Vaccine Market Forecast Value (2024-2032)
4 Global Autogenous Vaccine Market Landscape
4.1 Global Autogenous Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Autogenous Vaccine Product Landscape
4.2.1 Analysis by Strain Type
4.2.2 Analysis by End User
5 Global Autogenous Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Autogenous Vaccine Market Segmentation
6.1 Global Autogenous Vaccine Market by Strain Type
6.1.1 Market Overview
6.1.2 Bacterial Strain
6.1.3 Virus Strain
6.2 Global Autogenous Vaccine Market by End User
6.2.1 Market Overview
6.2.2 Veterinary Clinics
6.2.3 Veterinary Hospitals
6.2.4 Veterinary Research Institutes
6.2.5 Others
6.3 Global Autogenous Vaccine Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Autogenous Vaccine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Autogenous Vaccine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Autogenous Vaccine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Autogenous Vaccine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Autogenous Vaccine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Newport Laboratories, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Elanco Animal Health Inc
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Cambridge Technologies
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Hygieia Biological Laboratories
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 AniCon Labor GmbH
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Boehringer Ingelheim International GmbH
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Ceva Biovac
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Phibro Animal Health Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Ace Laboratory Services
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Huvepharma, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Global Autogenous Vaccine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global autogenous vaccines market reached a value of USD 129.4 million in 2023.
The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to reach a value of USD 212 billion by 2032.
The major drivers of the industry, such as rising disposable incomes, increasing population, rising prevalence of contagious diseases, changing lifestyles, and growing government funding, are expected to aid the market growth.
The key market trend guiding the growth of the market includes the growing focus on innovations for the prevention and treatment of zoonotic diseases.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading strain types in the market are bacterial strain and virus strain.
The major end use sectors in the market are veterinary clinics, veterinary hospitals, and veterinary research institutes, among others.
The major players in the industry are Newport Laboratories, Inc., Elanco Animal Health Inc., Cambridge Technologies, Hygieia Biological Laboratories, and AniCon Labor GmbH, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER